About Applied Therapeutics, Inc.
https://www.appliedtherapeutics.comApplied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications.
CEO
Les D. Funtleyder
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 12
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:21.4M
Value:$2.14M
VESTAL POINT CAPITAL, LP
Shares:14.25M
Value:$1.42M
PROPEL BIO MANAGEMENT, LLC
Shares:11.29M
Value:$1.13M
Summary
Showing Top 3 of 79
About Applied Therapeutics, Inc.
https://www.appliedtherapeutics.comApplied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1M ▲ | $17.76M ▲ | $-18.99M ▲ | -1.9K% ▼ | $-0.13 ▲ | $-18.88M ▲ |
| Q2-2025 | $0 | $13.18M ▼ | $-21.33M ▲ | 0% | $-0.15 | $-23.1M ▲ |
| Q1-2025 | $0 | $17.69M ▼ | $-21.82M ▼ | 0% | $-0.15 ▼ | $-25.52M ▲ |
| Q4-2024 | $0 ▼ | $21.33M ▼ | $44.01M ▲ | 0% ▲ | $0.32 ▲ | $-33.02M ▼ |
| Q3-2024 | $122K | $29.86M | $-68.59M | -56.22K% | $-0.48 | $-29.64M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $11.95M ▼ | $34.37M ▼ | $34.94M ▲ | $-561K ▼ |
| Q2-2025 | $30.42M ▼ | $37.34M ▼ | $19.9M ▼ | $17.44M ▼ |
| Q1-2025 | $50.76M ▼ | $56.91M ▼ | $20.24M ▼ | $36.67M ▼ |
| Q4-2024 | $79.4M ▼ | $86.69M ▼ | $29.68M ▼ | $57.01M ▲ |
| Q3-2024 | $98.87M | $106.57M | $100.67M | $5.89M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-18.99M ▲ | $-18.4M ▲ | $0 | $-75K ▼ | $-18.48M ▲ | $-18.4M ▲ |
| Q2-2025 | $-21.33M ▲ | $-20.34M ▲ | $0 | $0 | $-20.34M ▲ | $-20.34M ▲ |
| Q1-2025 | $-21.82M ▼ | $-28.64M ▼ | $0 | $0 | $-28.64M ▼ | $-28.64M ▼ |
| Q4-2024 | $44.01M ▲ | $-19.47M ▲ | $0 | $0 | $-19.47M ▲ | $-19.47M ▲ |
| Q3-2024 | $-68.59M | $-23.33M | $0 | $0 | $-23.33M | $-23.33M |
Revenue by Products
| Product | Q2-2024 | Q3-2024 | Q4-2024 | Q3-2025 |
|---|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Research and Development Services | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Les D. Funtleyder
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 12
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:21.4M
Value:$2.14M
VESTAL POINT CAPITAL, LP
Shares:14.25M
Value:$1.42M
PROPEL BIO MANAGEMENT, LLC
Shares:11.29M
Value:$1.13M
Summary
Showing Top 3 of 79